The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker

被引:0
|
作者
Michael L Salmans
Fang Zhao
Bogi Andersen
机构
[1] University of California,Departments of Medicine and Biological Chemistry
[2] Weill Cornell Medical College,Departments of Medicine and Genetic Medicine
来源
Breast Cancer Research | / 15卷
关键词
Breast Cancer; Estrogen Receptor; Tamoxifen; Endoplasmic Reticulum Stress; Fulvestrant;
D O I
暂无
中图分类号
学科分类号
摘要
Initially discovered as an estrogen-responsive gene in breast cancer cell lines, anterior gradient 2 (AGR2) is a developmentally regulated gene belonging to the protein disulfide isomerase (PDI) gene family. Developmentally, AGR2 is expressed in the mammary gland in an estrogen-dependent manner, and AGR2 knockout and overexpression mouse models indicate that the gene promotes lobuloalveolar development by stimulating cell proliferation. Although AGR2 overexpression alone seems insufficient for breast tumorigenesis in mice, several lines of investigations suggest that AGR2 promotes breast tumorigenesis. Overexpression of AGR2 in several breast cancer cell lines increases cell survival in clonogenic assays and cell proliferation, whereas AGR2 loss of function leads to decreased cell cycle progression and cell death. In addition, AGR2 was shown to promote metastasis of breast epithelial cells in an in vivo metastasis assay. As a PDI, AGR2 is thought to be involved in the unfolded protein response that alleviates endoplasmic reticulum stress. Since cancer has to overcome proteotoxic stress due to excess protein production, AGR2 may be one of many pro-survival factors recruited to assist in protein folding or degradation or both. When AGR2 is secreted, it plays a role in cellular adhesion and dissemination of metastatic tumor cells. In breast cancer, AGR2 expression is associated with estrogen receptor (ER)-positive tumors; its overexpression is a predictor of poor prognosis. The AGR2 gene is directly targeted by ER-alpha, which is preferentially bound in tumors with poor outcome. Whereas aromatase inhibitor therapy decreases AGR2 expression, tamoxifen acts as an agonist of AGR2 expression in ER-positive tumors, perhaps contributing to tamoxifen resistance. AGR2 is also overexpressed in a subset of ER-negative tumors. Furthermore, AGR2 expression is associated with the dissemination of metastatic breast cancer cells and can be used as a marker to identify circulating tumor cells and metastatic cells in sentinel lymph nodes. In conclusion, AGR2 is a promising drug target in breast cancer and may serve as a useful prognostic indicator as well as a marker of breast cancer metastasis.
引用
收藏
相关论文
共 50 条
  • [1] The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker
    Salmans, Michael L.
    Zhao, Fang
    Andersen, Bogi
    BREAST CANCER RESEARCH, 2013, 15 (02):
  • [2] Validating AGR2 Protein as a Potential Prostate Cancer Biomarker
    Hu, R.
    Drew, S.
    Huang, W.
    LABORATORY INVESTIGATION, 2014, 94 : 236A - 236A
  • [3] Validating AGR2 Protein as a Potential Prostate Cancer Biomarker
    Hu, R.
    Drew, S.
    Huang, W.
    MODERN PATHOLOGY, 2014, 27 : 236A - 236A
  • [4] Evaluation of the prognostic significance of anterior gradient 2 (AGR2) expression in invasive breast cancer
    Abuelmaaty, S. Raafat
    Mirza, S.
    Green, A. R.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S36 - S36
  • [5] Differential expression of anterior gradient gene AGR2 in prostate cancer
    Maresh, Erin L.
    Mah, Vei
    Alavi, Mohammad
    Horvath, Steve
    Bagryanova, Lora
    Liebeskind, Emily S.
    Knutzen, Laura A.
    Zhou, Yong
    Chia, David
    Liu, Alvin Y.
    Goodglick, Lee
    BMC CANCER, 2010, 10
  • [6] Differential expression of anterior gradient gene AGR2 in prostate cancer
    Erin L Maresh
    Vei Mah
    Mohammad Alavi
    Steve Horvath
    Lora Bagryanova
    Emily S Liebeskind
    Laura A Knutzen
    Yong Zhou
    David Chia
    Alvin Y Liu
    Lee Goodglick
    BMC Cancer, 10
  • [7] H10 peptide, a promising therapeutic and diagnosis tool to target Anterior Gradient protein 2 (AGR2) in cancer.
    Garri, C.
    Howell, S.
    Ghaffarizadeh, A.
    Juarez, E.
    Macklin, P.
    Agus, D.
    Kani, K.
    Roberts, R.
    MOLECULAR BIOLOGY OF THE CELL, 2016, 27
  • [8] Identification and functional characterization in the Anterior Gradient 2 isomerase disulfide protein (AGR2): potential role in cholangiocarcinoma
    Higa, A.
    Mulot, A.
    Delom, F.
    Bioulac-Sage, P.
    Lepreux, S.
    Balabaud, C.
    Bouchecareilh, M.
    Nguyen, D. T.
    Boismenu, D.
    Wise, M. J.
    Chevet, E.
    BULLETIN DU CANCER, 2011, 98 : S30 - S30
  • [9] TESTING AGR2 AS AN EARLY CANCER BIOMARKER
    Wulandari, R.
    Menon, U.
    Pereira, S. P.
    Timms, J. F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E2 - E2
  • [10] Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype
    Kani, Kian
    Malihi, Paymaneh D.
    Jiang, Yuqiu
    Wang, Haiying
    Wang, Yixin
    Ruderman, Daniel L.
    Agus, David B.
    Mallick, Parag
    Gross, Mitchell E.
    PROSTATE, 2013, 73 (03): : 306 - 315